Sigilon Therapeutics, Inc. announced that as previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the ?SEC?) by Sigilon Therapeutics, Inc. (the ?Company?), on June 28, 2023, the Company entered into an Agreement and Plan of Merger (the ?Merger Agreement?) with Eli Lilly and Company (?Parent?), and Parent?s wholly owned subsidiary, Shenandoah Acquisition Corporation (?Purchaser?). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Rogerio Vivaldi Coelho, M.D., Douglas G. Cole, M.D., John Cox, Stephen N. Oesterle, M.D., Kavita Patel, M.D., Robert R. Ruffolo, Jr., Ph.D. and Eric D. Shaff) resigned as directors of the Company. These resignations were in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company?s operations, policies or practices.